ADLAI NORTYE GROUP LTD
ANLNASDAQTrading Snapshot
- Day Range
- $15.45 – $15.75
- 52-Week Range
- $0.88 – $17.25
- Volume
- $2.45B
- Avg Volume
- $2.48B
- Shares Outstanding
- 53.1M
- Next Earnings
- Oct 19, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $7M
- P/E Ratio
- -8.0
- P/S Ratio
- 42.2x
- EPS (TTM)
- $-1.41
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +22.5%
Why Investors Own ANL
- ✓High-growth profile — revenue up +26.5% YoY with expanding US Equity exposure.
- ✓Healthy economics — 53% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
ADLAI NORTYE GROUP LTD
ANL
StockOtter · stockotter.spaceAbout ADLAI NORTYE GROUP LTD
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Adlai Nortye Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-in-Class Pan-RAS(ON) Inhibitor-Based ADC
First-in-class CEACAM5-targeting ADC armed with a pan-RAS(ON) inhibitor – designed for tumor-selective RAS pathway inhibition First patient dosed in Australia; global Phase I initiated U.S. FDA cleared IND with "Study-Ma
Wall Street Analysts See an 81.78% Upside in Adlai Nortye Ltd. Sponsored ADR (ANL): Can the Stock Really Move This High?
The consensus price target hints at an 81.8% upside potential for Adlai Nortye Ltd. Sponsored ADR (ANL).
Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress
Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical oncologists appointed t
Adlai Nortye (ANL) to Announce Quarterly Earnings on Thursday
Adlai Nortye (NASDAQ: ANL - Get Free Report) is projected to announce its Q2 2026 resultson Thursday, August 6th. Analysts expect Adlai Nortye to announce earnings of ($0.1333) per share and revenue of $3.95 million for
Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia
First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA and China NMPA are in pr
Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025
First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on preclinical data Both QD